The FDA approved the Vabysmo 6-mg single-dose prefilled syringe for the treatment of wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion, according to a Genentech press release.
Vabysmo (faricimab-svoa, Genentech) was previously approved for wet AMD, DME and retinal vein occlusion (RVO), according to the release, with the pre-filled syringe (PFS) offering an “alternative, ready-to-use format” for delivering the drug. It is the first and only bispecific antibody approved for the eye, with its approval supported by positive